188 results about "Hemangioma" patented technology

The present invention discloses an anti-tumor compound and its preparation method,application, and pharmaceutical compositions. The anti-tumor compound is a 4 - nitro-substituted benzyl group ifosfamide ester prodrug thereof, or pharmaceuticallysalt, or solvate thereof of the structure of formula I. The structure of formula I. The present invention has the following advantage of being used for the treatment or prevention of mammalian tumor-related diseases, such as leukemia, hemangioma, glioma, Kaposi's sarcoma, ovarian cancer, breast cancer, lung cancer, pancreatic cancer, lymphoma, prostate, colon and skin tumors and their complications.

The invention discloses a biodegradable fabric body capable of being developed and a conveying device. A biodegradable mesh grid serves as a main body. The biodegradable fabric body capable of being developed and the conveying device are characterized in that at least two layers of a sealing layer, a development control layer and a promotion endothelial cell growth layer are arranged on the surface of the mesh grid; the biodegradable mesh grid is woven by composite materials which are obtained by one or various biodegradable high molecular materials in a blending or a copolymerization mode; a form of the biodegradable fabric body is geometry composed of one or a plurality of quadric surfaces and comprises a mushroom shape composed of a spherical shape, a double-elliptical external form and double spherical caps and variants thereof; the mesh grid is a single-layer mesh or a double-layer mesh woven by biodegradable silk. After being implanted into hemangioma, the biodegradable fabric body capable of being developed and the conveying device have a shape memory function and enough mechanical strength, can play a role of embolism blocking hemangioma in a short term and are good in sealing performance. Degraded fragments cannot come off to blood to cause an embolism. The biodegradable fabric body capable of being developed and the conveying device have good biological safety, and the possibility that the degraded fragments cause the embolism is lowered.

The invention discloses a retina hemangioma image segmentation method based on a GAN (Generative Adversarial Network), and the method comprises the steps: constructing a GAN structure, wherein the GANstructure comprises a generator and a discriminator, the generator comprises a plurality of downsampling layers and an equal number of upsampling layers, and the discriminator comprises a plurality of downsampling layers; taking a hemangioma artificial segmented image and an original fundus retina image as training data, performing iterative training of the GAN, and obtaining an optimal generator; performing hemangioma image segmentation of a to-be-segmented fundus retina image based on the optimal generator. Compared with a conventional retina hemangioma image segmentation method based on animage processing algorithm, the method can achieve the more accurate and clear segmentation of the image, reduces a false positive segmentation result, and is more precise in image segmentation details.

The invention belongs to the technical field of medicines, and provides a propranolol hydrochloride (PPL.HCL) gel which can be externally used for treating infant superficial hemangioma. The propranolol hydrochloride gel is mainly prepared from propranolol hydrochloride, gel matrix, a percutaneous penetration enhancer, a preservative, a humectant and the like. By using the propranolol hydrochloride gel, adverse reactions such as decreased heart rate, cyanosis, airway hyperresponsiveness, shortage of granular leukocytes, diarrhoea, sleep change and blood sugar reduction caused by orally taking propranolol by hemangioma patients can be reduced and even avoided, and the problems that oral dosage is not easy to control, infants inconveniently take medicines and the like are solved.

Methods of generating and expanding human hemangio-colony forming cells and non-engrafting hemangio cells in vitro and methods of expanding and using such cells are disclosed. The methods permit the production of large numbers of hemangio-colony forming cells, non-engrafting hemangio cells as well as derivative cells, such as hematopoietic and endothelial cells. The cells obtained by the methods disclosed may be used for a variety of research, clinical, and therapeutic applications. Human non-engrafting hemangio cells are a novel progenitor cell population that is related to but distinct from the hemangioblast and human hemangio-colony forming cells. The invention also provides compositions, preparations, and solutions comprising hemangio-colony forming cells, non-engrafting hemangio cells or cells differentiated therefrom. The compositions, preparations, and solutions include cryopreserved preparations and substantially purified preparations, as well as mixed compositions formulated in combination with related hemangioblast progenitor cell types that can engraft into the bone marrow.

The invention provides the application of tetracyclic triterpenoids compound cucurbitacins E in preparing anti-angiogenic drugs. The cucurbitacins E can inhibit tumor angiogenesis, arthritis pathological tissue vessel angiogenesis, neovascular eye disease, hemangioma pathological tissue angiogenesis, psoriasis pathological tissue vessel angiogenesis, solid tumor pathological tissue angiogenesis, hemangioma, Kaposi' s sarcoma pathological tissue angiogenesis, leukocythemia, lymphadenoma, myeloma blood cancer and Paget' s disease angiogenesis. The invention also provides the application of a compound containing effective dose of cucurbitacins E and pharmacy acceptable ingredients in preparing the anti-angiogenic drugs.

Disclosed are compounds which are non-peptide, reversible inhibitors of type 2 methionine aminopeptidase, useful in treating conditions mediated by angiogenesis, such as cancer, haemangioma, proliferative retinopathy, rheumatoid arthritis, atherosclerotic neovascularization, psoriasis, ocular neovascularization and obesity.

The invention relates to the field of medicines, in particular to an angiogenesis inhibitor for inhibiting several matrix metal protein enzyme and inhibiting the transfer of the vascular endothelial cell, which can be applied to preparation and treatment of entity tumor and rheumatoid arthritis. The polypeptide comprises a polypeptide I, polypeptide II, polypeptide III and polypeptide IV (Seq NO.1, Seq NO.2, Seq NO.3, Seq NO.4); The polypeptide can be used for treating entity tumor and rheumatoid arthritis. The four angiogenesis inhibitors can be applied to preparation of medicine for treating tumor, and is characterized in that: the tumor is derived from primary of neck, brain, thyroid gland, esophagus, pancreas, lung, liver, stomach, mammary gland, kidney, colon or rectum, ovary, cervix, uterus, prostate, bladder and testis or secondary cancer, melanoma, hemangioma and sarcoma.

The invention relates to the field of medicines, and in particular relates to an inhibitor of angiogenesis capable of inhibiting matrix metallo-proteinase and migration of vascular endothelial cells. The inhibitor can be used for preventing and treating solid tumor and rheumatoid arthritis. The polypeptide specifically means polypeptide I, polypeptide II, polypeptide III and polypeptide IV (with reference to SeqNO.1, SeqNO.2, SeqNO.3 and SeqNO.4). The polypeptide can be used for treating solid tumor and rheumatoid arthritis. The four inhibitors of angiogenesis can be applied to preparing medicines for treating tumor. The polypeptide is characterized in that tumor is originated from essential or subsequent cancers, melanoma, hemangioma and sarcoma of heat and neck, brain, thyroid, esophagus, pancreas, lung, liver, stomach, breast, kidney, gall bladder, colon or rectum, ovary, cervix uterus, uterus, prostate, bladder and testis.

This invention concerns a method of treating hemangiomas with a beta blocker by applying the beta blocker onto the hemangiomas directly. The invention also concerns a combination therapy by using a beta blocker along with a corticosteroid or an alpha adrenergic receptor agonist for the treatment of hemangiomas.

The invention provides an application of osthole in preparing anti-angiogenic drugs. The osthole can inhibit tumor angiogenesis, arthritis pathological tissue vessel angiogenesis, neovascular eye disease, hemangioma pathological tissue angiogenesis, psoriasis pathological tissue vessel angiogenesis, solid tumor pathological tissue angiogenesis, hemangioma, Kaposi's sarcoma pathological tissue angiogenesis, leukocythemia, lymphadenoma, myeloma blood cancer and Paget's disease angiogenesis. The invention also provides the application of a compound containing effective dose of osthole and pharmacy acceptable ingredients in preparing the anti-angiogenic drugs.

The invention discloses a sodium alginate microballoon vein suppository containing hemangioma-resisting medicant, a preparation method and an application thereof. The sodium alginate microballoon vein suppository comprises carrier sodium alginate and hemangioma-resisting medicant; the sodium alginate covers the hemangioma-resisting medicant; the weight ratio of the sodium alginate to the hemangioma-resisting medicant is 5:1-60:1; and the hemangioma-resisting medicant is pingyangmycin, sodium morrhuate, carbamide or bleocin. The raw materials used in the invention have favorable mechanical strength, biocompatibility, biological degradability and stability, have no organic solvent, and are basically harmless to functions of hemopoietic system and immune system, thereby suppository can be industrially produced.

The invention discloses a developable sealed type woven body implantation material, which comprises a woven mesh, a sealing film and a developing layer and is characterized in that the woven mesh is a single-layer or double-layer nickel-titanium alloy mesh, the developing layer is one layer of coated developing materials, the sealing film is sewed into any one layer of the single-layer or double-layer nickel-titanium alloy mesh, then, an endothelial cell growth promotion layer is coated at the outer surface of the sealing film, and the developing layer is arranged among or outside any layer of the woven mesh, the sealing film and the endothelial cell growth promotion layer. The conveying device comprises an outer sheath tube (32), an inner sheath tube (31) and a conveying guide wire (30), wherein the inner sheath tube (31) is sheathed in the outer sheath tube (32) and is glidingly connected with the outer sheath tube (32). The woven body implantation material is in a self-expansion type, the integral developing can be realized, the sealing film can seal and isolate the hemangioma, the endothelial cell growth promotion layer promotes the growth of endothelial cells in the surface of the woven body implantation material, the woven body implantation material is coated inside endothelial tissues of blood vessels, and the risk of recent and future thrombus generation is reduced.

Disclosed are compounds of the formula: wherein the formula variables are as defined herein. The compounds of this invention are non-peptide, reversible inhibitors of type 2 methionine aminopeptidase. Also disclosed is the use of such compounds in treating conditions mediated by angiogenesis, such as cancer, haemangioma, proliferative retinopathy, rheumatoid arthritis, atherosclerotic neovascularization, psoriasis, ocular neovascularization and obesity.

The invention provides a diabetic retinopathy classification system based on uncertainty, and relates to the technical field of neural networks. The method includes obtaining an exudation segmentationimage and a micro-hemangioma segmentation image by using the two trained segmentation network models; fusing the exudation segmentation image, the micro-hemangioma segmentation image and the corresponding preprocessed fundus image into a multi-channel image, extracting features by using a trained Bayesian deep learning classification network model, and giving out accidental uncertainty and modeluncertainty by a classification module while finally outputting a model classification result. Therefore, the safety performance of the model is guaranteed, and when a diagnosis image cannot give a result very definitely, whether artificial experts are needed for re-diagnosis or not can be determined through two uncertainty degrees, so that the model is safer and more reliable in clinical use.

The invention discloses an external medicament for treating infant hemangioma and a preparation method thereof, which belong to the technical field of medicine. The external medicament comprises the following components: propranolol, stearic acid, glycerin monostearate, white Vaseline, azone, oleic acid, Tween-80, glycerol, deionized water and ethylparaben. The method comprises the following steps of: accurately weighing a certain amount of greasy component and a certain amount of water-soluble component respectively, and heating and preserving heat respectively at 75+ / -2 DEG C; and slowly adding the greasy component into the water-soluble component, and continuously stirring along the same direction till the mixture is fully emulsified and is condensed into paste. The external medicament is safe and reliable. As proved by clinical experiments, after the external medicament is uniformly smeared onto the surface of a tumor body, the tumor body is faded remarkably 2-3 months later, 59 percent of infant patients can be cured 5-7 months later, 33 percent of tumor bodies are faded remarkably, and the total yield is 92 percent.

The invention relates to a decapeptide inhibiting angiogenesis and use thereof, belonging to the technical field of biological medicine. The decapeptide inhibiting angiogenesis provided by the invention is deprived from human Homo sapien with an amino acid sequence of YNWNSFGLRF and the molecular weight of 1303.4, and is named as Kp-10. The invention further provides use of the decapeptide inhibiting angiogenesis for preparing medicines for inhibition of angiogenesis, in particular relevant use of Kp-10 for preparing medicines for inhibition of angiogenesis dependent diseases such as cancer, rheumatoid arthritis, psoriasis, diabetes syndrome, and hemangioma. A series of experimental results in VEGF (Vascular Endothelial Growth Factor) induction shows that Kp-10 has obvious inhibition function in the proliferation experiment of human umbilical vein endothelial cells (HUVEC), transfer experiment, micro-tube forming experiment, angiogenesis experiment of chick embryo allantois and mouse cornea experiment, and the decapetide can be used for preparing medicines for inhibiting angiogenesis.

The invention provides a Chinese medicine composition capable of effectively treating cutaneous hemangioma, belonging to the field of Chinese medicines. the Chinese medicine composition for treating cutaneous hemangioma is characterized by being prepared from the Chinese medicinal herbs in parts by weight: 10 parts of astragalus mongholicus, 10 parts of rhizoma smilacis glabrae, 8 parts of dangshen, 12 parts of unprocessed rehmannia root, 15 parts of polygonum multiflorum, 20 parts of radices lithospermi, 12 parts of moutan bark, 15 parts of white paeony root, 8 parts of rhizoma corydalis, 5 parts of golden cypress, 5 parts of rhizoma anemarrhenae, 15 parts of Chinese thorowax root, 12 parts of radix curcumae, 12 parts of rhizoma sparganii, 10 parts of curcuma zedoary, 15 parts of calculus bovis and 20 parts of safflower carthamus. The Chinese medicine composition is prepared from the natural Chinese medicinal herbs as raw materials, is used for treating the cutaneous hemangioma by using combined action of all Chinese medicinal herbs, has no toxic and side effects to a human body, and has the advantages of low cost, capability of treating both principal and secondary aspect of the cutaneous hemangioma, and accurate treatment effect. Proved by 100 patients in clinical, the Chinese medicine composition for treating the cutaneous hemangioma has a cure rate of 96.0 percent, wherein 96 patients are cured and 4 patients get better.

The invention belongs to the technical field of medicines, and provides a propranolol hydrochloride (PPL.HCL) gel which can be externally used for treating infant superficial hemangioma. The propranolol hydrochloride gel is mainly prepared from propranolol hydrochloride, gel matrix, a percutaneous penetration enhancer, a preservative, a humectant and the like. By using the propranolol hydrochloride gel, adverse reactions such as decreased heart rate, cyanosis, airway hyperresponsiveness, shortage of granular leukocytes, diarrhoea, sleep change and blood sugar reduction caused by orally taking propranolol by hemangioma patients can be reduced and even avoided, and the problems that oral dosage is not easy to control, infants inconveniently take medicines and the like are solved.

The invention discloses an interferon microneedle, as well as a preparation method thereof and application of the interferon microneedle in preparation of medicaments for treating hemangioma. The interferon microneedle comprises interferon which is one of naturally extracted interferon, gene recombinant expressed interferon, polyethylene glycol-modified interferon, glycosylation-modified interferon and human albumin fused interferon, wherein the interferon microneedle is prepared from the interferon and polymer; or the surface of the microneedle is coated with a layer of mixture of the interferon and auxiliaries keeping activity of the interferon to prepare the interferon microneedle. Compared with the prior art, the novel medical application of the interferon microneedle opens up a new application field, and the microneedle has the advantages of safe administration, no toxic or side effect, good compliance, patient pain relieving, low price and the like and can be easily accepted by patients.

Aiming to solve the problems that the mechanical property of the implant is reduced and that the mineralization bone is not easily formed in the implant existing in the technology for preparing the biomedical porous implant, the invention provides a biomedical porous implant and a method for preparing the same. The method comprises the following steps of: interweaving threads of the implant material to form a netty structure; pressing the netty structure into an implant coarse blank with a special shape; sintering the implant coarse blank so as to allow the material threads at cross points in the netty structure to form melting connection to prepare the implant. The plantation body prepared by the method can be used for preparing biomedical porous nickel-titanium alloy implants such as denda, artificial joints and the like and realizing the deep freezing treatment of hemangioma, ecphymata and keloid by carrying liquid nitrogen.

The invention discloses a biforked stent with a membrane, which consists of a stent backbone and two stent branches. The stent backbone is respectively communicated with the two stent branches; the whole stent with the membrane has a 'Y'-shaped structure; and the front end of the stent with the membrane is biforked. Compared with the prior art, the biforked stent with the membrane has the advantages that the stent and a vessel are stably embedded under the situation of not obviously influencing the running of blood stream, thereby effectively sealing the inner port of a hemangioma; meanwhile, as the stent is combined with the vessel on three directions, the stent is hard to fall off, thus greatly improving the safety; and the stent completely protects the part of the biforked position of the vessel directly impacted by the blood stream, thereby effectively reinforcing the inner wall of the vessel.

The invention discloses a timolol external preparation for treating hemangioma. The prepared external preparation is ointment or gel prepared in the mode that two active ingredients including timolol and oleum menthae are added into a gel matrix or an ointment matrix, wherein the content of the timolol, by mass, accounts for 0.25-1% of the ointment or the gel, and the content of the oleum menthae, by mass, accounts for 1% of the ointment or the gel. The preparation method comprises the steps that timolol is prepared into a timolol saline solution in a salifying mode, the active ingredient oleum menthae is added into the timolol saline solution, the obtained solution is dispersed into the gel matrix according to the weight ratio of (1:1)-(1:10) to be subjected to swelling, and the gel is obtained; or the obtained solution is dispersed into the ointment matrix according to the weight ratio of (2.5:1)-(3:1), and the ointment is obtained. The preparation process is simple, easy to practice and applicable to requirements of industrial mass production. Pharmacodynamics results prove that the effective ingredients timolol and oleum menthae in the external preparation have the synergism for treating hemangioma and good tolerance, and no adverse reaction occurs.

The invention discloses an early warning system for ruptured artery hemangioma and an early warning method thereof. According to the invention, an ultrathin flexible sensor, ultrathin flexible temperature sensors and an ultrathin flexible strain sensor are implanted into the body through minimally invasive surgery; the strain sensor is wound and attached to the position of the hemangioma; the temperature sensors are wound and attached to the equidistant positions upstream and downstream the hemangioma; the early warning system has ultrahigh biological compatibility and will not cause internal rejection reaction; the sensors are directly and tightly attached to the measured positions and can be used for timely and accurately measuring the measured parameters; the ultrathin flexible characteristics of the sensors will not cause new focus by resulting in external damage to blood vessels and tissues; the signal is transmitted to a mobile terminal in the manner of near field communication; a microprocessor in the mobile terminal has an alarming function; when a deforming value or local blood pressure value of the hemangioma exceeds a threshold value, the microprocessor can alarm, so that the early warning system can conveniently monitor and measure early warning for a long time.

The invention belongs to the field of preparations and relates to a timolol maleate pharmaceutical composition and a preparation method thereof. The timolol maleate pharmaceutical composition contains timolol maleate, Carbopol, triethanolamine, propylene glycol, ethylparaben and water. The pharmaceutical composition has the advantages of good biocompatibility, easiness in coating, no greasiness and the like, and the use compliance of a patient is greatly improved; the timolol maleate pharmaceutical composition can directly act on a focus of infection, and the local drug concentration is increased, so that the drug effect is furthest exerted, and the untoward effect of the whole body caused due to oral medication or intravenous medication is avoided; and the pharmaceutical composition is suitable for industrial large-scale production, is used for treating hemangioma and is particularly suitable for treating superficial type infantile hemangioma.

Methods for treating diseases or disorders of the skin which are characterized by angiogenesis have been developed using curcumin and curcumin analogs. Based on the results obtained with curcumin, it has been determined that other angiogenesis inhibitors can also be used to treat these skin disorders. It has further been discovered that curcumin acts to inhibit angiogenesis in part by inhibition of basic fibroblast growth factor (bFGF), and thereby provides a means for treating other disorders characterized by elevated levels of bFGF, such as bladder cancer, using curcumin and other analogues which also inhibit bFGF. Representative skin disorders to be treated include the malignant diseases angiosarcoma, hemangioendothelioma, basal cell carcinoma, squamous cell carcinoma, malignant melanoma and Karposi's sarcoma, and the non-malignant diseases or conditions including psoriasis, lymphangiogenesis, hemangioma of childhood, Sturge-Weber syndrome, verruca vulgaris, neurofibromatosis, tuberous sclerosis, pyogenic granulomas, recessive dystrophic epidermolysis bullosa, venous ulcers, acne, rosacea, eczema, molluscum contagious, seborrheic keratosis, and actinic keratosis.

The invention provides a maleic acid timolol preparation for treating infant superficial hemangioma and application of the maleic acid timolol preparation. The maleic acid timolol preparation adopts water as a dispersing medium and comprises the following components by mass percent with the total percent of 100%: 0.1-1% of maleic acid timolol and 0.5-2% of hyaluronic acid or hyaluronate. The maleic acid timolol preparation provided by the invention is relatively good in viscosity and convenient for medical operators to rub on patients, a film can be formed on the skin surface, the adhesion time is greatly prolonged, and active components can play roles continuously; the maleic acid timolol preparation has a moisturizing function and is not dried within a short time, so that the skin surface can be kept in a wet state for a long time; as the keratoderma of an infant is thin and the water content is higher than that of an adult, the moisturizing function is particularly important for infant skin, however, hyaluronic acid or hyaluronate is not used in infant preparation dressing yet at present; in addition, application of hyaluronic acid or hyaluronate to the dressing shows by accident that the function of promoting wound healing of infant skin can be achieved.

The invention discloses an externally applied traditional Chinese medicine powder for diminishing inflammation and swelling, which is prepared from the following raw material medicines by weight percentage: 20-30% of realgar, 25-35% of rhubarb, 10-20% of turmeric, 10-20% of cortex phellodendri, and 10-20% of bulbus fritillariae thunbergii. The externally applied powder for diminishing swelling isprepared by the compatibility of only five raw material medicines, has the efficacies of promoting blood circulation and removing blood stasis, diminishing swelling and relieving pain, expelling stasis and stagnation, and promoting pus discharge and tissue regeneration. The externally applied traditional Chinese medicine powder is simple in compatibility, distinct in treatment effect, and short in course of treatment, and does not have toxic or side effect. The externally applied powder for diminishing swelling can treat acute and chronic lobular hyperplasia of mammary glands, lymphnoditis, mumps, traumatic injuries, lipoma, furuncle, pustule of finger tip, paronychia, tinea unguium, external piles, anus abscess and hemangioma, with wide treatment range and low cost, and also can be used for treating mammary gland disease and foot-and-mouth disease of cows, with very good treatment effect.

Compounds of this invention are non-peptide, reversible inhibitors of type 2 methionine aminopeptidase, useful in treating conditions mediated by angiogenesis, such as cancer, haemangioma, proliferative retinopathy, rheumatoid arthritis, atherosclerotic neovascularization, psoriasis, ocular neovascularization and obesity.